DWM
CPRX

Dakota Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Dakota Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$283K Sell
11,414
-4,277
-27% -$102K 0.01% 663
2025
Q4 		$366K Buy
+15,691
New +$350K 0.01% 612
2025
Q3 		– Sell
-12,988
Closed -$282K – 676
2025
Q2 		$282K Buy
12,988
+1,893
+17% +$44.7K 0.01% 639
2025
Q1 		$269K Sell
11,095
-225
-2% -$5.07K 0.01% 646
2024
Q4 		$236K Buy
+11,320
New +$243K 0.01% 681

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dakota Wealth Management's CPRX Position: Q1 2026 in Review

Dakota Wealth Management reduced its Catalyst Pharmaceutical (CPRX) stake by 27% in Q1 2026, selling an estimated $102K and leaving 11,414 shares worth $283K. The position accounts for 0.01% of the portfolio, ranked #663.

Dakota Wealth Management first reported a position in CPRX in Q4 2024 and has held it in 5 quarters since. The position peaked at $366K in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Dakota Wealth Management held 11,414 shares of Catalyst Pharmaceutical worth $283K as of Q1 2026.
  • Dakota Wealth Management sold 4,277 Catalyst Pharmaceutical shares in Q1 2026, an estimated $102K.
  • Catalyst Pharmaceutical made up 0.01% of Dakota Wealth Management's portfolio in Q1 2026, its #663 holding.
  • Dakota Wealth Management first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 5 quarters since.
  • Dakota Wealth Management's Catalyst Pharmaceutical position peaked at $366K in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Dakota Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.